PMCF Study to Evaluate Performance and Safety of "LUXIDROPIN BABY & JUNIOR"

Exclusion Criteria

• •Preterm newborns;
• •Pediatric subjects with congenital abnormalities of the eye, physical trauma, corneal infiltrate or ulcers in either eye. Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant based on predefined values;
• •Pediatric subjects with/without eye infections requiring treatment with topical or systemic antibiotics;
• •Previous eye surgery;
• •Suspected other - different - eyes clinical conditions (e.g. glaucoma);
• •Suspected known hypersensitivity or allergy to Investigational Product (IP) components;
• •Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. diabetes);
• •Participation in another investigational study;
• •Parent(s)' and/or patients' inability to follow all study procedures, including attending all site visits, tests and evaluations;
• •Parent(s)' and/or patients' mental incapacity that precludes adequate understanding or cooperation.